Across the recent three months, 5 analysts have shared their insights on Arcturus Therapeutics (NASDAQ:ARCT), expressing a variety of opinions spanning from bullish to bearish. The table below ...
Neda Safarzadeh, Sr. Director, Head of IR, PR & Marketing, Arcturus Therapeutics Holdings Inc., San Diego, CA, USA, Tel: +1-858-900-2682 Arcturus Therapeutics, based ...
BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive COVID-19 vaccine approval in Europe was reassuring for a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback